Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Mumps Vaccine in Infants
NCT04364399Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Nov 2020
- Primary completion
- Nov 2020
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of mumps vaccine, live in mumps (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Seroconversion rate of hemagglutination inhibition (HI) antibody. Started Nov 2020; status: completed.
02
Drugs
mumps vaccine, live
03
Conditions
mumps
Beyond the preview
Go deeper on NCT04364399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04364399.